Skip to main content
Premium Trial:

Request an Annual Quote

Roche and GE Healthcare Partner on Alzheimer s Drug-Response Study

NEW YORK, July 11 (GenomeWeb News) - Roche and GE Healthcare will collaborate on a personalized approach to treating Alzheimer's disease, the companies said today.


The companies will partner on controlled clinical trials in which patients taking a Roche anti-amyloid drug candidate for Alzheimer's disease will be monitored for drug response using GE's positron emission tomography diagnostic imaging agent.


This PET-based technology is able to monitor levels of beta-amyloid, a form of brain plaque believed to cause memory loss in Alzheimer's disease patients. The companies said that this plaque could previously only be confirmed during autopsy.


Roche and GE Healthcare said they will independently analyze patient data and share information to validate the efficacy of the therapeutic product and the PET-based diagnostic tool.


This data will enable Roche and GE to submit "necessary and comprehensive data to regulatory authorities for approvals," the companies said.


Financial terms were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.